MedTrace Logo

A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA

NCT05476081 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2239

Last updated 2024-12-05

No results posted yet for this study

Summary

The REAl-life study on short-term Dual Antiplatelet treatment in Patients with ischemic stroke or Transient ischemic attack (READAPT) is an observational, multicenter, prospective study involving Italian centers. The study aims at evaluating effectiveness and safety of short-term (21-90 days) dual antiplatelet treatment (DAPT) in secondary prevention of mild-to-moderate ischemic stroke or high-risk TIA.

Conditions

Interventions

DRUG

Aspirin

Aspirin (100-300 mg) administered for 21-90 days in combination with another antiplatelet treatment

DRUG

Clopidogrel

Clopidogrel (75-600 mg) administered for 21-90 days in combination with another antiplatelet treatment

DRUG

Ticagrelor

Ticagrelor (90-180 mg) administered for 21-90 days in combination with another antiplatelet treatment

Sponsors & Collaborators

  • University of L'Aquila

    lead OTHER

Principal Investigators

  • Simona Sacco, MD · Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-03
Primary Completion
2023-02-03
Completion
2023-05-03

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05476081 on ClinicalTrials.gov